ES2811090T8 - Terapéuticos dirigidos a proteínas truncadas de poliposis adenomatosa coli (apc) - Google Patents

Terapéuticos dirigidos a proteínas truncadas de poliposis adenomatosa coli (apc)

Info

Publication number
ES2811090T8
ES2811090T8 ES14843412T ES14843412T ES2811090T8 ES 2811090 T8 ES2811090 T8 ES 2811090T8 ES 14843412 T ES14843412 T ES 14843412T ES 14843412 T ES14843412 T ES 14843412T ES 2811090 T8 ES2811090 T8 ES 2811090T8
Authority
ES
Spain
Prior art keywords
apc
proteins
adenomatous polyposis
polyposis coli
therapeutics targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14843412T
Other languages
English (en)
Other versions
ES2811090T3 (es
Inventor
Jef Debrabander
Jerry W Shay
Wentian Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2811090T3 publication Critical patent/ES2811090T3/es
Publication of ES2811090T8 publication Critical patent/ES2811090T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES14843412T 2013-09-10 2014-09-10 Terapéuticos dirigidos a proteínas truncadas de poliposis adenomatosa coli (apc) Active ES2811090T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361875933P 2013-09-10 2013-09-10
US201461930754P 2014-01-23 2014-01-23
PCT/US2014/054987 WO2015038644A2 (en) 2013-09-10 2014-09-10 Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins

Publications (2)

Publication Number Publication Date
ES2811090T3 ES2811090T3 (es) 2021-03-10
ES2811090T8 true ES2811090T8 (es) 2022-09-29

Family

ID=52666505

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14843412T Active ES2811090T3 (es) 2013-09-10 2014-09-10 Terapéuticos dirigidos a proteínas truncadas de poliposis adenomatosa coli (apc)

Country Status (16)

Country Link
US (2) US9856233B2 (es)
EP (1) EP3044218B1 (es)
JP (1) JP6506291B2 (es)
KR (2) KR102300576B1 (es)
CN (1) CN105873913B (es)
AU (2) AU2014318821B2 (es)
BR (1) BR112016005252A2 (es)
CA (1) CA2924062C (es)
DK (1) DK3044218T3 (es)
ES (1) ES2811090T3 (es)
HK (1) HK1224291A1 (es)
MX (1) MX2016003082A (es)
RU (1) RU2727516C2 (es)
SG (1) SG11201601850YA (es)
WO (1) WO2015038644A2 (es)
ZA (2) ZA201601798B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102300576B1 (ko) 2013-09-10 2021-09-08 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 절단된 선종성 결장 폴립증 (ａｐｃ) 단백질을 타겟화하는 치료제
US10082496B2 (en) 2014-09-10 2018-09-25 Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
CA2991420A1 (en) * 2015-07-15 2017-01-19 The Board Of Regents Of The University Of Texas System Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
CA3015817A1 (en) 2016-03-09 2017-09-14 President And Fellows Of Harvard College Direct palladium-catalyzed aromatic fluorination
CN114652735A (zh) * 2016-07-27 2022-06-24 凯斯西储大学 促进髓鞘形成的化合物和方法
WO2019126702A1 (en) 2017-12-22 2019-06-27 Case Western Reserve University Compounds for promoting myelination
CN108250111B (zh) * 2018-01-15 2020-04-28 华南理工大学 一种双受体有机发光小分子材料及其制备方法和应用
US20220024891A1 (en) * 2018-12-04 2022-01-27 The Board Of Regents Of The University Of Texas System Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer
CN113624665A (zh) * 2021-07-30 2021-11-09 中国药科大学 一种抗肿瘤候选化合物在治疗结直肠癌药物中的应用及测定方法
EP4558481A1 (en) * 2022-07-22 2025-05-28 Biogen MA Inc. Emopamil-binding protein inhibitors and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH0667926B2 (ja) * 1985-11-12 1994-08-31 旭化成工業株式会社 環状のイソキノリンスルホンアミド誘導体
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JP2001172257A (ja) 1999-10-05 2001-06-26 Fujisawa Pharmaceut Co Ltd 有機スルホンアミド化合物
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
WO2002070469A2 (en) * 2001-03-05 2002-09-12 Icos Corporation Selective pde3b inhibitors and use of the same in therapy
DE10155684A1 (de) * 2001-11-13 2003-05-22 Bayer Ag Thiazolharnstoffe
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
US20060035884A1 (en) * 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
EP1866298A2 (en) * 2005-03-31 2007-12-19 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006134481A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
CN101466670B (zh) * 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US8603465B1 (en) * 2006-08-07 2013-12-10 Merck Sharp & Dohme, Corp. Methods for treatment of polyposis
AU2008296479A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CN102027133A (zh) 2008-05-07 2011-04-20 温瑟瑞克斯有限公司 鉴定调节癌细胞中Wnt信号传导的化合物的方法
US9623109B2 (en) * 2008-05-27 2017-04-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of killing cells and use of same in prevention and treatment of cancer
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
CA2874998A1 (en) 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
WO2013119950A2 (en) 2012-02-08 2013-08-15 Insight Genetics, Inc. Methods and compositions relating to fusions of ros1 for diagnosing and treating cancer
US20130330761A1 (en) 2012-06-12 2013-12-12 Celcuity, LLC Whole cell assays and methods
KR102300576B1 (ko) 2013-09-10 2021-09-08 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 절단된 선종성 결장 폴립증 (ａｐｃ) 단백질을 타겟화하는 치료제

Also Published As

Publication number Publication date
US20190135776A1 (en) 2019-05-09
MX2016003082A (es) 2016-09-13
CN105873913B (zh) 2019-12-03
ZA201805172B (en) 2019-08-28
AU2018202898A1 (en) 2018-05-17
JP6506291B2 (ja) 2019-04-24
KR20180011890A (ko) 2018-02-02
JP2016534140A (ja) 2016-11-04
CA2924062C (en) 2019-05-14
KR20160049014A (ko) 2016-05-04
RU2727516C2 (ru) 2020-07-22
CA2924062A1 (en) 2015-03-19
US10577344B2 (en) 2020-03-03
SG11201601850YA (en) 2016-04-28
WO2015038644A2 (en) 2015-03-19
EP3044218A4 (en) 2017-02-22
DK3044218T3 (da) 2020-07-27
EP3044218B1 (en) 2020-05-27
AU2014318821A1 (en) 2016-04-14
AU2014318821B2 (en) 2018-04-19
US20150232444A1 (en) 2015-08-20
CN105873913A (zh) 2016-08-17
RU2016113279A (ru) 2017-10-16
KR102300576B1 (ko) 2021-09-08
US9856233B2 (en) 2018-01-02
KR101824230B1 (ko) 2018-01-31
HK1224291A1 (zh) 2017-08-18
WO2015038644A3 (en) 2015-05-14
EP3044218A2 (en) 2016-07-20
ES2811090T3 (es) 2021-03-10
BR112016005252A2 (pt) 2017-09-12
ZA201601798B (en) 2022-05-25

Similar Documents

Publication Publication Date Title
ES2811090T8 (es) Terapéuticos dirigidos a proteínas truncadas de poliposis adenomatosa coli (apc)
EP3317294A4 (en) STABILIZED ANTIMICROBIAL PEPTIDES
DK3019190T3 (da) Kationiske neurotoksiner
EP3291824A4 (en) ANTIMICROBIAL THERAPY
IL244879B (en) Aqueous herbicidal concentrates
DK2951203T3 (da) Heterodimere proteiner
DK2994154T3 (da) Antimikrobielt peptid
DK3368678T3 (da) Genetisk konstrukt
EP2989885A4 (en) HARVESTER
HUE060756T2 (hu) Fungicid hatású készítmények
CL2016000219A1 (es) Proteinas de fusión terapéutica.
DK3041857T3 (da) Protein a-kromatografi
HUE051184T2 (hu) Baktériumalapú fehérjeszállítás
EP3355931C0 (en) PROTEIN CONJUGATES
BR112017014838A2 (pt) benzoxaboróis microbicidas
EP2958889A4 (en) NEOSEPTINE: SMALL MOLECULAR ADJUVANZIA
DE112014004954T8 (de) Abgabesystem
DK3288955T3 (da) Bortezomib-baseret afgivelsessystem
DE112014003026A5 (de) Steuergerät
DE112014004938T8 (de) Abgabesystem
DE112014002718T8 (de) Führungssystem
EP3043644C0 (en) Antimicrobial composition
EP2980085A4 (en) pyrazole
BR112016003583A2 (pt) compostos herbicidas
EP2959776A4 (en) HERBICIDE COMPOSITION